YD Bio Limited (YD Bio), a biotechnology company pioneering DNA methylation-based cancer detection technologies and ophthalmologic innovations, announced that its business partner, EG Biomed US Inc. (EG BioMed), has been accredited by the College of American Pathologists (CAP) Laboratory Accreditation Programme for its CLIA-certified facility in Bothell, Washington (CLIA Certificate #50D2316600). EG BioMed is one of YD Bio’s key licensing partners for pancreatic and breast cancer detection and collaborates with 3D Global to develop treatments for eye disorders.

The CAP accreditation — widely regarded as the gold standard in laboratory quality assurance — confirms that EG BioMed meets the highest international standards in laboratory operations. In conjunction with its existing CLIA certification, this accreditation enhances EG BioMed’s capability to deliver advanced laboratory-developed tests (LDTs) in support of YD Bio’s cancer detection and diagnostic initiatives across the United States.

“We are delighted that our partner, EG BioMed, has achieved this highly respected accreditation,” said Dr Ethan Shen, Founder, Chairman and Chief Executive Officer of YD Bio Limited. “This milestone underscores our shared commitment to precision, scientific excellence, and improved patient outcomes. CAP accreditation reinforces our ability to deliver dependable, cutting-edge diagnostics while solidifying our position as a trusted innovator in precision medicine.”

With CAP accreditation now secured, YD Bio and EG BioMed plan to expand their diagnostic portfolio with a continued focus on early cancer detection and disease monitoring. Alongside YD Bio’s ophthalmology products and other advanced healthcare solutions, the company remains dedicated to improving patient care and quality of life through innovation.

Demonstrating continued scientific leadership, Ruo-Kai Lin, Chief R&D Officer at EG BioMed and Professor at Taipei Medical University, presented new research findings at the American Association for Cancer Research (AACR) Special Conference on Advances in Pancreatic Cancer Research, held in Boston from 28 September to 1 October 2025. Her presentation unveiled a novel circulating cell-free DNA biomarker capable of monitoring metastasis and disease progression in advanced pancreatic cancer.

YD Bio Limited continues to drive innovation across clinical trials, new drug development, cancer prevention diagnostics, and regenerative medicine, including stem cell and exosome-based therapies, aimed at transforming the treatment landscape for diseases with significant unmet medical needs.